First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

First Tracks Biotherapeutics, Inc. (TRAX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Announced ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms in Cohort

Event · Earnings
Original reporting
Published Nov 3, 2026, 9:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 9:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$TRAX
Bullish
high confidence
Mentioned
$TRAX
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$TRAXBullishHigh
01

Why it matters

The trial data and cash raise are likely to drive short‑term price appreciation, while the broader autoimmune‑biotech sector may see renewed investor interest.

02

Market read

The announcement provides fresh, material data that can move TRAX and potentially influence peer biotech stocks.

03

What to watch

The $200M placement dilutes existing shareholders and may signal higher cash burn than anticipated.

Relevance 8/10Novelty 9/10Timing: today
AlphAI · Earnings readTRAX · Third Quarter 2026 · ended Sept. 30, 2026

First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

→Mixed quarter

Third-quarter net loss and research and development expense were lower than the comparable 2025 period, ANB033 reported positive Phase 1b Cohort 1 data in celiac disease, and the company completed a $200 million private placement. Results remain those of a clinical-stage company with no reported revenue, ongoing losses, and multiple development and regulatory milestones ahead.

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Research and development expenses, three months ended September 30, 2026GAAP$23.8M––
Research and development expenses, nine months ended September 30, 2026GAAP$83.4M––
General and administrative expenses, three months ended September 30, 2026GAAP$9M––
General and administrative expenses, nine months ended September 30, 2026GAAP$37.1M––
Total operating expenses, three months ended September 30, 2026GAAP$32.84M––
Total operating expenses, nine months ended September 30, 2026GAAP$120.6M––
Loss from operations, three months ended September 30, 2026GAAP−$32.84M––
Loss from operations, nine months ended September 30, 2026GAAP−$120.6M––
Interest income, three months ended September 30, 2026GAAP$1.50M––
Interest income, nine months ended September 30, 2026GAAP$5.39M––
Other expense, net, three months ended September 30, 2026GAAP−$7K––
Other expense, net, nine months ended September 30, 2026GAAP−$9K––
Total other income (expense), net, three months ended September 30, 2026GAAP$1.49M––
Total other income (expense), net, nine months ended September 30, 2026GAAP$5.38M––
Net loss, three months ended September 30, 2026GAAP$31.4M––
Net loss, nine months ended September 30, 2026GAAP$115.2M––
Net loss per common share, basic and diluted, three months ended September 30, 2026GAAP$(0.88)––
Net loss per common share, basic and diluted, nine months ended September 30, 2026GAAP$(3.25)––
Comprehensive loss, three months ended September 30, 2026GAAP−$31.36M––
Comprehensive loss, nine months ended September 30, 2026GAAP−$115.2M––
Weighted-average number of shares outstanding, basic and diluted, three months ended September 30, 2026GAAP35.75M––
Weighted-average number of shares outstanding, basic and diluted, nine months ended September 30, 2026GAAP35.42M––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

2027 and H1 2027/Q1 2027/Q3 2027 outlook

  • NoteTop-line data from Phase 1b Cohort 2 in celiac disease anticipated in Q1 2027.
  • NoteAnticipate initiating a late-stage clinical trial in celiac disease in 2027.
  • NoteTop-line data from the Phase 1b trial in eosinophilic esophagitis anticipated in Q3 2027.
  • NotePlan to initiate Phase 2 development of ANB033 in vitiligo and one additional indication in H1 2027.
  • NoteCompetitor registrational data in systemic lupus erythematosus and cutaneous lupus erythematosus anticipated in Q4 2026 and early 2027, respectively.

What drove it

  • Research and development expense declined primarily because of decreased development costs for rosnilimab and ANB032, offset by increased costs relating to the Phase 1 trial for ANB033.
  • The increase in nine-month general and administrative expense was due to allocated legal costs for the separation from AnaptysBio, Inc. and AnaptysBio, Inc.'s lawsuit with GSK and Tesaro.
  • ANB033 achieved a statistically significant and clinically meaningful protective effect on gluten-induced intestinal damage and symptoms in the Phase 1b celiac disease gluten-challenge cohort.
  • ANB033 was well tolerated with no safety signals observed in the Phase 1b gluten-challenge cohort.

Concerns

  • The company reported a net loss of $31.4 million for the three months ended September 30, 2026.
  • No revenue was reported in the filing.
  • The separation of AnaptysBio, Inc. and First Tracks Biotherapeutics, Inc. was completed on April 20, 2026; results for January 1, 2026 to April 19, 2026 and for the three and nine months ended September 30, 2025 include assets, liabilities, and expenses related to both companies.
  • Rosnilimab is subject to an assessment of return-on-equity-maximizing strategic options rather than an announced development plan.

What to watch

  • Top-line data from the ANB033 Phase 1b celiac disease mucosal-healing cohort anticipated in Q1 2027.
  • Initiation of a late-stage ANB033 clinical trial in celiac disease anticipated in 2027.
  • Initiation of ANB033 Phase 2 development in vitiligo and one additional indication planned for H1 2027.
  • Top-line data from the ANB033 Phase 1b eosinophilic esophagitis trial anticipated in Q3 2027.
  • The potential development approach for ANB101 following anticipated competitor registrational data in Q4 2026 and early 2027.

Balance sheet and cash flow

  • Cash, cash equivalents and investments totaled $155.6 million as of Sept. 30, 2026.
  • Pro forma cash was $343 million following a $200 million private placement completed in Oct. 2026.
  • Cash and cash equivalents were $155,627 (in thousands) at September 30, 2026, compared with $238,196 (in thousands) at December 31, 2025.
  • Short-term investments were — at September 30, 2026, compared with $73,442 (in thousands) at December 31, 2025.
  • Total assets were $170,456 (in thousands) at September 30, 2026, compared with $330,545 (in thousands) at December 31, 2025.
  • Total current liabilities were $18,090 (in thousands) at September 30, 2026, compared with $31,023 (in thousands) at December 31, 2025.
  • Total stockholders' equity was $151,011 (in thousands) at September 30, 2026, compared with $287,490 (in thousands) at December 31, 2025.

Analysis

First Tracks reported a $31.4 million GAAP net loss, or $0.88 per diluted share, for the three months ended September 30, 2026, compared with a $41.9 million net loss, or $1.50 per diluted share, in the comparable 2025 period. Research and development expense was $23.8 million versus $33.3 million, while general and administrative expense was $9.0 million versus $11.7 million. The company reported no revenue.

The expense profile reflects lower development costs for rosnilimab and ANB032, partly offset by higher ANB033 Phase 1 costs. For the nine months ended September 30, 2026, research and development expense was $83.4 million compared with $114.1 million, while general and administrative expense was $37.1 million compared with $28.2 million. The company attributed the nine-month general and administrative increase to allocated legal costs associated with the separation from AnaptysBio, Inc. and AnaptysBio, Inc.'s lawsuit with GSK and Tesaro.

The main operating development was positive top-line Phase 1b Cohort 1 data for ANB033 in celiac disease. The filing reported a least squares mean change from baseline in villus height-to-crypt depth ratio of -0.17 on ANB033 versus -0.66 on placebo, with a +0.49 placebo-adjusted delta and p =0.009. It also reported a least squares mean change in intraepithelial lymphocyte density of -1.20 on ANB033 versus +18.83 on placebo, with a -20.03 placebo-adjusted delta and p <0.001. The company said ANB033 prevented an increase in symptoms throughout the gluten challenge and was well tolerated with no safety signals observed.

Liquidity was augmented by a $200 million private placement completed in October 2026. Cash, cash equivalents and investments totaled $155.6 million as of Sept. 30, 2026, and the company reported pro forma cash of $343 million following the financing. The near-term clinical calendar centers on celiac disease Cohort 2 top-line data in Q1 2027, initiation of a late-stage celiac disease trial in 2027, Phase 2 starts in vitiligo and one additional indication in H1 2027, and eosinophilic esophagitis top-line data in Q3 2027.

Comparability requires attention because the separation was completed on April 20, 2026. Financial results from January 1, 2026 to April 19, 2026 and for the three and nine months ended September 30, 2025 include assets, liabilities, and expenses related to both First Tracks and AnaptysBio. Rosnilimab remains under review for return-on-equity-maximizing strategic options, while ANB101's potential development approach is being evaluated in light of clinical and translational evidence and anticipated competitor data.

Management, verbatim

ANB033, a subcutaneously administered CD122 antagonist designed to inhibit signaling of both IL-15 and IL-2 on immune cells, demonstrated statistically significant protection against gluten-induced intestinal damage and symptoms and was well tolerated in the Phase 1b gluten-challenge cohort.

Daniel Faga, president and chief executive officer

We anticipate initiating Phase 2 development in vitiligo and one additional indication in the first half of 2027, and reporting top-line results from the celiac disease mucosal-healing cohort in the first quarter of 2027 and in eosinophilic esophagitis in the third quarter of 2027.

Daniel Faga, president and chief executive officer

Not in the filing

stated, not guessed
  • Revenue
  • Revenue segments
  • Gross profit and gross margin
  • Non-GAAP financial measures
  • Operating cash flow
  • Free cash flow
  • Debt
  • Share repurchases
  • Dividends
  • Financial revenue guidance
  • Financial gross-margin guidance
  • Financial operating-expense guidance
  • Financial tax-rate guidance
  • Prior-quarter comparisons
  • Prior outlook for comparison

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

First Tracks Biotherapeutics reported Q3 2026 results, highlighted a successful Phase 1b trial for ANB033, and raised $200M in a private placement.

Company-level read

Ticker impact

$TRAXBullishHigh confidence
Context

Announced positive Phase 1b results for ANB033 in celiac disease and completed a $200M private placement, boosting cash to $343M.

Expected impact

likely upside as investors price in the favorable Phase 1b results and stronger balance sheet

Evidence & confidence

Statistically significant efficacy, Fast Track designation and new cash reduce financing risk and de‑risk the pipeline.

Market effects

Boosts sentiment for the autoimmune‑biotech niche and may lift peers developing CD or eosinophilic esophagitis therapies.

Minimal direct regional effect; primarily U.S. biotech market.

Adds to global pipeline momentum for CD treatments, but impact confined to biotech investors.

Counterpoint

If later‑stage data fail to confirm Phase 1b efficacy, the current hype could reverse sharply.

Key entities

  • First Tracks Biotherapeutics, Inc.

    Clinical‑stage biotech developing ANB033 and other immune‑modulating antibodies.

  • ANB033

    CD122 antagonist showing statistically significant efficacy in a Phase 1b celiac disease trial.

Every TRAX earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$TRAXMedAI 8/10

First Tracks Biotherapeutics (TRAX) Reports Positive ANB033 Celiac Cohort Results

First Tracks Biotherapeutics (TRAX) reported positive Phase 1b trial results for ANB033 in celiac disease, showing significant protection against gluten-induced damage. The company expects mucosal-healing data in Q1 2027 and eosinophilic esophagitis results in Q3 2027. It also anticipates late-stage trials for celiac disease and Phase 2 trials for vitiligo in 2027. The company raised $200 million in a private placement, bringing pro forma cash to $343 million.

$TRAXMedAI 9/10

First Tracks Biotherapeutics reports positive Phase 1b ANB033 topline results in celiac disease

First Tracks Biotherapeutics reported positive Phase 1b results for ANB033, showing significant protection against gluten-induced intestinal damage in celiac disease patients. The treatment reduced IEL density, improved histology, and lowered symptom scores. No severe adverse events were reported. The company plans to advance ANB033 to late-stage development in 2027, with Cohort 2 data expected in Q1 2027.